Stocks and Investing
Stocks and Investing
Tue, October 16, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, October 15, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Maintained (BLUE) at Hold with Decreased Target to $186 on, Oct 15th, 2018
Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Hold with Decreased Target from $190 to $186 on, Oct 15th, 2018.
Matthew has made no other calls on BLUE in the last 4 months.
There is 1 other peer that has a rating on BLUE. Out of the 1 peers that are also analyzing BLUE, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Josh Schimmer of "Evercore ISI Group" Upgraded from Hold to Buy and Increased Target to $230 on, Tuesday, June 19th, 2018
Contributing Sources